Entries by Philip Rye

AlgiPharma appoints new CFO

AlgiPharma appoints Fredrik Alpsten as new Chief Financial Officer (CFO) Mr Alpsten has an MSc degree from Stockholm School of Economics. He has 25 years of operational, financial, and strategic business experience as an executive in the life science field. He has served as Senior Vice President and CFO of Boule Diagnostics AB, a Swedish […]

New 2b Clinical Trial started in Australia

New Phase 2b Clinical Trial: A phase 2b, randomised, double-blind, study of alginate oligosaccharide (OligoG) dry powder inhalation on top of standard of care compared to placebo on top of standard of care in patients with Cystic Fibrosis (CF). (ORDCF-205) A new clinical study was initiated with a Clinical Trial Investigator Meeting held on 29th […]

AlgiPharma Appoints Director for Australian Operations

AlgiPharma has appointed a new director Marieta Ryan to lead the recently established Australian office and to facilitate clinical trial operations in Australia. Marieta was officially appointed in mid-2018 and is actively involved in two of AlgiPharma’s multinational clinical phase 2b studies with clinical sites in Europe, Australia and New Zealand. About Cystic Fibrosis: Cystic […]

AlgiPharma receives up to an additional $3 million from the US Cystic Fibrosis Foundation (CFF)

AlgiPharma AS announced an agreement with Cystic Fibrosis Foundation (CFF), Bethesda, MD., that will provide up to $3 million to support further research and development of AlgiPharma’s drug candidate (OligoG) for the treatment of people with cystic fibrosis. This is in addition to more than $11.5 million already received from the Cystic Fibrosis Foundation for Phase 2 clinical work.